0001735726-20-000001.txt : 20201021 0001735726-20-000001.hdr.sgml : 20201021 20201021141438 ACCESSION NUMBER: 0001735726-20-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20201021 DATE AS OF CHANGE: 20201021 EFFECTIVENESS DATE: 20201021 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OncoNano Medicine, Inc. CENTRAL INDEX KEY: 0001735726 IRS NUMBER: 811713330 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-378478 FILM NUMBER: 201250345 BUSINESS ADDRESS: STREET 1: 550 RESERVE STREET STREET 2: SUITE 190 CITY: SOUTHLAKE STATE: TX ZIP: 76092 BUSINESS PHONE: (682) 712-1581 MAIL ADDRESS: STREET 1: 550 RESERVE STREET STREET 2: SUITE 190 CITY: SOUTHLAKE STATE: TX ZIP: 76092 D 1 primary_doc.xml X0708 D LIVE 0001735726 OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 SOUTHLAKE TX TEXAS 76092 (682) 285-1411 DELAWARE None None Corporation true Ravi Srinivasan c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Executive Officer Director John Dyett c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Director Alvaro Guillem c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Executive Officer Director Joydeep Goswami c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Director Matthew Head c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Executive Officer Jeff Keyser c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Executive Officer Caleb Smith c/o OncoNano Medicine, Inc. 181 Grand Avenue, Suite 225 Southlake TX TEXAS 76092 Director Biotechnology Decline to Disclose 06b false 2020-10-15 false true false 0 Salem Partners LLC 43363 None None 11111 Santa Monica Blvd., Suite 2250 Los Angeles CA CALIFORNIA 90025 AZ ARIZONA CA CALIFORNIA CO COLORADO FL FLORIDA IN INDIANA MA MASSACHUSETTS NV NEVADA NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA OR OREGON PA PENNSYLVANIA TX TEXAS false 60000000 21467152 38532848 false 21 0 1073358 true The broker earned $1,073,358 in cash and will earn a (1) 5.0% cash fee on any later sales and (2) warrant to purchase shares of common stock equal to 4.0% of the number of shares sold in the aggregate transaction. 0 false OncoNano Medicine, Inc. /s/ Alvaro Guillem Alvaro Guillem Interim CEO 2020-10-20